Form 4: Opus Genetics Director James S. Manuso Receives Stock and Option Grants

Director James S. Manuso of Opus Genetics, Inc. was granted 79,504 shares of common stock and options to purchase 79,592 shares on April 30, 2025.

Summary

• On April 30, 2025, James S. Manuso, a director of Opus Genetics, Inc., received a grant of 79,504 shares of common stock.
• These restricted stock units vest on the earlier of the one-year anniversary of the grant date or the day before the next annual meeting of stockholders, contingent upon continued service.
• Manuso also received options to purchase 79,592 shares of common stock at an exercise price of $0.95 per share.
• These options also vest on the earlier of the one-year anniversary of the grant date or the day before the next annual meeting of stockholders, contingent upon continued service, and expire on April 29, 2035.
• Following these transactions, Manuso directly owns 261,763 shares of Opus Genetics, Inc.

Sentiment

Score: 7

Explanation: The document indicates standard compensation practices, suggesting stability and alignment of interests. The grants are positive for incentivizing the director, but the overall impact is neutral without further context.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting conditions encourage continued service and commitment to the company's success.

Risks

• The value of the stock and options is dependent on the future performance of Opus Genetics, Inc.
• If the company does not perform well, the value of these grants may be limited.

Future Outlook

The vesting of the stock and options is contingent upon the director's continued service, suggesting an expectation of ongoing involvement with the company.

Industry Context

Stock and option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in biotech companies of similar size and stage as Opus Genetics.
• The vesting schedule of one year or until the next annual meeting is also typical to ensure continued service and alignment with shareholder interests.
• Comparing the size of the grant to similar companies would require more detailed benchmarking data on director compensation practices in the biotech sector.

Stakeholder Impact

• Shareholders may view the grants positively as they align the director's interests with the company's long-term success.
• The director benefits from the potential appreciation in the value of the stock and options.

Key Dates

Keywords

Opus Genetics, Director, Stock Grant, Stock Options, Form 4, Beneficial Ownership, IRD